[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Lumos Diagnostics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100609241",false,"NCT07211997","FebriDx® Pediatric Validation Study","FebriDx® Pediatric Validation Study Protocol","Inclusion Criteria:\n\n* Signed informed consent by parent\u002Fguardian and Assent for ages 7-11 years\n* Exhibit or report of a new onset measured temperature (oral or tympanic) of greater than or equal to 100.4°F\u002F38°C within 3 days (72 hours) of enrollment\n* Clinical suspicion for Acute Respiratory Infection beginning within 7 days before enrollment AND presents with at least one of the following new onset of symptoms: runny nose, nasal congestion, sore throat, cough, hoarse voice, shortness of breath \u002F difficulty breathing\n\nExclusion Criteria:\n\n* Unwilling to participate in 7-day follow-up or sign HIPAA waiver to obtain medical record if hospitalized\n* Immunocompromised state or taking immunosuppressive or chemotherapeutic medications in the last 30 days (e.g. oral \u002F inhaled steroids, Methotrexate, Cyclosporine, Chemotherapy, interferon therapy)\n* Taking antibiotics or antiviral therapy in the last 14 days\n* Received a live viral immunization in the last 14 days\n* Clinical diagnosis of otitis media or recognizable viral syndrome (i.e., croup, varicella, stomatitis) at the time of enrollment\n* Prior enrollment in the study","ALL","2 Years","11 Years",{"count":19,"type":20},800,"ESTIMATED","OBSERVATIONAL","The primary objective of this study is to determine performance characteristics of the FebriDx® test in differentiating bacterial from non-bacterial etiology among febrile pediatric patients (2-11 years) presenting to the emergency department, urgent care center or primary care office with a suspected acute respiratory tract infection.",[24],"Acute Respiratory Infections (ARIs)",[26,27,28,29,30,31],"Pediatric","Host immune response","Biomarkers","Point-of-Care","Myxovirus resistance protein A (MxA)","C-reactive protein (CRP)","RECRUITING","2025-10-30",{"date":35,"type":36},"2025-10-31","ACTUAL",{"date":38,"type":36},"2025-10-09",{"date":40,"type":20},"2026-11-30",{"name":42,"class":43},"Lumos Diagnostics","INDUSTRY",10,""]